SCHEMBL25484262

SCHEMBL25484262

CCCCCCCCCCCCCCN(C(=O)OC(C)C(C)C)C(C)CCCCCCCCCCCC

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.37
ABCB1 P08183 1/20 0.37
LMNA P02545 2/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
ACE2 Q9BYF1 1/20 0.36
EPHX2 P34913 1/20 0.35
GPR84 Q9NQS5 3/20 0.35
FFAR1 O14842 1/20 0.35
CA1 P00915 1/20 0.35
ZDHHC7 Q9NXF8 1/20 0.35
MAPT P10636 1/20 0.34
TP53 P04637 1/20 0.34
LCK P06239 1/20 0.34
PPARD Q03181 1/20 0.34
ZDHHC20 Q5W0Z9 1/20 0.34
ZDHHC2 Q9UIJ5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25484313 0.91 CTSK (0.38) FAAHABCB1LMNACNR1CNR2
SCHEMBL6895826 0.79 LMNA (0.42) FAAHABCB1LMNACA1ZDHHC7
SCHEMBL14870606 0.79 LMNA (0.42) FAAHABCB1LMNACA1ZDHHC7
SCHEMBL14870608 0.79 LMNA (0.42) FAAHABCB1LMNACA1ZDHHC7
SCHEMBL10087789 0.76 MGLL (0.42) FAAHABCB1LMNACA1ZDHHC7
SCHEMBL10087790 0.76 MGLL (0.42) FAAHABCB1LMNACA1ZDHHC7
SCHEMBL14229463 0.74 EPHX2 (0.48) ACE2EPHX2GPR84FFAR1CA1
SCHEMBL3370091 0.74 EPHX2 (0.51) ACE2EPHX2GPR84FFAR1
SCHEMBL6894229 0.74 CA2 (0.47) FAAHABCB1LMNACNR1CNR2
SCHEMBL6894231 0.74 CA2 (0.47) FAAHABCB1LMNACNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150941-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150941-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS GABBR1, GABBR2, GABRE FAAH 565/4885ABCB1 908/4885LMNA 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.